Current Report Filing (8-k)
March 27 2017 - 09:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 27, 2017
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware
|
001-11993
|
05-0489664
|
(State of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
1600 Broadway, Suite 700, Denver, Colorado
|
80202
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (720) 697-5200
1600 Broadway, Suite 950, Denver, Colorado
80202
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure.
On March 27, 2017,
BioScrip, Inc. (the “Company”), issued a press release in connection with the Company’s upcoming investor meetings,
a copy of which is furnished herewith as Exhibit 99.1. In conjunction with these meetings, the Company is publishing an updated
investor presentation to the investor relations section of its website.
The information in
this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information
in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended. The Company undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report and cautions that the information included in this Current Report under Item 7.01,
including Exhibit 99.1, is current only as of March 27, 2017 and may change thereafter. The furnishing of the information in this
report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report
is material or complete, or that investors should consider this information before making an investment decision with respect to
any security of the Company.
Forward-Looking
Statements
This current report
includes statements that may constitute “forward-looking statements,” that involve substantial risks and uncertainties,
including the statements regarding 2017 guidance, the anticipated effects of the UnitedHealth contract termination and other statements
regarding the Company’s plans and strategies. These statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical
or current facts. In some cases, forward-looking statements can be identified by words such as “may,” “should,”
“could,” “anticipate,” “estimate,” “expect,” “project,” “outlook,”
“aim,” “intend,” “plan,” “believe,” “predict,” “potential,”
“continue” or comparable terms. Because such statements inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results
may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could
cause or contribute to such differences include but are not limited to risks associated with: the Company’s ability to integrate
the acquisition of Home Solutions, the Company’s ability to grow its core Infusion revenues, the Company’s ability
to continue to experience positive results from its financial improvement plan to reduce operating costs; the Company’s ability
to comply with the covenants in its debt agreements; the UnitedHealth contract termination, including potential accounting charges
and impacts on other contract provisions and their associated revenue; the success of the Company’s initiatives to mitigate
the impact of the Cures Act on its business; reductions in federal, state and commercial reimbursement for the Company’s
products and services; increased government regulation related to the health care and insurance industries; as well as the risks
described in the Company’s periodic filings with the Securities and Exchange Commission. The Company does not undertake any
duty to update these forward-looking statements after the date hereof, even though the Company’s situation may change in
the future. All of the forward-looking statements in this report are qualified by these cautionary statements.
Item 9.01. Financial Statements and
Exhibits
(d) Exhibits
Exhibit No.
|
|
Description
|
99.1
|
|
Press release issued by the Company, dated March 27, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
Date: March 27, 2017
|
|
/s/ Kathryn Stalmack
|
|
By:
|
Kathryn Stalmack
|
|
|
Senior Vice President, General Counsel and Secretary
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press release issued by the Company, dated March 27, 2017.
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2023 to Mar 2024